A case of anaphylaxis to alemtuzumab

  • Charles J. S. NyeEmail author
  • Annette Wagner
  • Onajite Kousin-Ezewu
  • Joanne L. Jones
  • Alasdair J. Coles
Letter to the Editors

Dear Sirs,

Alemtuzumab (Lemtrada) is a humanised monoclonal antibody targeting CD52 found on lymphocytes and monocytes, and is a highly effective treatment of relapsing–remitting multiple sclerosis [1, 2, 3]. At baseline five consecutive daily doses of 12 mg IV are given, with no further treatment until 12 months later, when patients receive three consecutive doses of 12 mg IV.

Over 90% of patients receiving alemtuzumab experience infusion-associated reactions. Work in the 1990s showed that these could be reduced or ameliorated by pretreatment with corticosteroids [4] and that the underlying mechanism was a programmed release of cytokines from natural killer cells, triggered by Fc cross-linking [5]. When severe, these reactions may include a rash, fever, hypotension and bronchospasm and so mimic anaphylaxis; they are, therefore, termed “anaphylactoid”. This phenomenon has led to confusion in the current literature as to whether patients may develop genuine anaphylaxis to alemtuzumab.




The patient was treated on the NIHR Cambridge Clinical Research Facility.


The Medical Research Council funded the CAMTHY trial.

Compliance with ethical standards

Conflicts of interest

Both AC and JJ have received honoraria and travel costs for attending scientific advisory boards.

Ethical standards

All human studies have been approved by the appropriate ethics committee and have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The patient in this case study gave her informed consent for the report to be written.


  1. 1.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828CrossRefGoogle Scholar
  2. 2.
    Coles AJ, CAMMS223 Trial Investigators Compston DAS, Selmaj KW, Lake SL, Moran S et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801CrossRefGoogle Scholar
  3. 3.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839CrossRefGoogle Scholar
  4. 4.
    Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46(3):296–304CrossRefGoogle Scholar
  5. 5.
    Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996 98(12):2819–2826CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH et al (2015) Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and rebif® efficacy in multiple sclerosis (CARE-MS) program. Int J MS Care 17(4):191–198CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23(13):2971–2979CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.University of CambridgeCambridgeUK
  2. 2.Department of Allergy and ImmunologyCambridge University Hospitals NHS Foundation TrustCambridgeUK
  3. 3.Department of Clinical NeurosciencesCambridge University Hospitals NHS Foundation TrustCambridgeUK

Personalised recommendations